Original Articles

The Impact of Metformin Treatment on Serum Level of AMH and on Ovulation and Pregnancy Outcome in Women With PCOS

Abstract

Anti-Müllerian Hormone (AMH) AMH inhibits follicle recruitment and may reduce FSH action, contributing to ovulatory issues in females. PCOS patients often receive metformin treatment. This study aimed to investigate metformin's effect on serum AMH levels in PCOS women and its impact on ovulation and pregnancy rates. This interventional study was performed between June 2023 and June 2024. 100 PCOS women attending the infertility departments of Maternity Teaching Hospital in Adiwniyah province, Iraq, were invited to participate in the study. PCOS was diagnosed based on the Rotterdam consensus statements criteria. Metformin was given to 50 women (study group) and 50 women received placebo o serve as a control group. After 3 months, comparison of mean serum AMH between study groups revealed significant variation (P=0.020) and this significant variation became more pronounced 6 months later (P<0.001). In case of placebo group, comparison of baseline mean serum AMH to those after 3 months and after 6 months revealed minimal no significant changes (P>0.05); whereas the use of metformin resulted in significant reduction of mean serum AMH 3 months later (P=0.006) and the reduction was more significant 6 months later (P<0.001). The rate of ovulation and the rate of positive pregnancy test were reported to be higher significantly in metformin group in contrast to placebo group (P=0.001 and 0.016, respectively). Metformin treatment is efficient and safe in reducing serum AMH in women with PCOS, thus indicating reduction in antral follicle count and changes in overall hormonal status that can improve ovulation and pregnancy in those women.

1. Sumanth N, Soumya P, Tabassum A, Mamatha P, Yamini G, Meghamala K, et al. A study to assess the co-morbidities and complications of polycystic ovarian syndrome. Cell Mol Biomed Rep 2023;3:107-13.
2. Abd Al-Kareem TA, Hassan SA, Abdalhadi SM. Polycystic ovary syndrome: pathogenesis, management, and treatment with metals and organic compounds. Cell Mol Biomed Rep 2024;4:54-64.
3. Rudnicka E, Kunicki M, Calik-Ksepka A, Suchta K, Duszewska A, Smolarczyk K, et al. Anti-Müllerian hormone in pathogenesis, diagnostic and treatment of PCOS. Int J Mol Sci 2021;22:12507.
4. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001;142:4891-9.
5. Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. The physiology and clinical utility of anti-Müllerian hormone in women. Hum Reprod Update 2014;20:370-85.
6. Sivanandy MS, Ha SK. The role of serum anti-Müllerian hormone measurement in the diagnosis of polycystic ovary syndrome. Diagnostics 2023;13:907.
7. Zhou Z, Chen H, Chu L, Zou Q, Chen Q, Yang J, et al. The effects of metformin on anti-Müllerian hormone levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis. J Ovarian Res 2023;16:123.
8. European Medicines Agency. Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function; 2016.
9. U.S. Food and Drug Administration. FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function; 2017.
10. Brackett CC. Clarifying metformin's role and risks in liver dysfunction. J Am Pharm Assoc 2010;50:407-10.
11. Papazafiropoulou A, Melidonis A. Antidiabetic agents in patients with hepatic impairment. World J Meta-Anal 2019;7:380-8.
12. Emslie-Smith AM, Boyle DI, Evans J, Sullivan F, Morris AD, DARTS/MEMO Collaboration. Contraindications to metformin therapy in patients with type 2 diabetes: a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18:483-8.
13. Hoofnagle JH. LiverTox: a website on drug-induced liver injury. In: Drug-Induced Liver Disease. Amsterdam: Elsevier; 2013:725-32.
14. Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, et al. Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril 2005;83:130-6.
15. Neagu M, Cristescu C. Anti-Müllerian hormone: a prognostic marker for metformin therapy efficiency in the treatment of women with infertility and polycystic ovary syndrome. J Med Life 2012;5:462.
16. Grigoryan O, Absatarova J, Andreeva E, Melnichenko G, Dedov I. Effect of metformin on the level of anti-Müllerian hormone in therapy of polycystic ovary syndrome in obese women. Minerva Ginecol 2014;66:85-9.
17. Madsen HN, Lauszus FF, Trolle B, Ingerslev HJ, Tørring N. Impact of metformin on anti-Müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial. Acta Obstet Gynecol Scand 2015;94:547-51.
18. Dewailly D, Robin G, Peigne M, Decanter C, Pigny P, Catteau-Jonard S. Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. Hum Reprod Update 2016;22:709-24.
19. Chhabra N, Malik S. Effect of insulin sensitizers on raised serum anti-Müllerian hormone levels in infertile women with polycystic ovarian syndrome. J Hum Reprod Sci 2018;11:348-52.
20. Foroozanfard F, Samimi M, Almadani KH, Sehat M. Effect of metformin on the anti-Müllerian hormone level in infertile women with polycystic ovarian syndrome. Electron Physician 2017;9:5969-73.
21. Panidis D, Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Decavalas G, et al. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecol Endocrinol 2011;27:587-92.
22. Nascimento AD, Lara LAS, Rosa-e-Silva AC, Ferriani RA, Reis RM. Effects of metformin on serum insulin and anti-Müllerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. Gynecol Endocrinol 2013;29:246-9.
23. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009;30:1-50.
24. Magkos F, Hjorth MF, Astrup A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16:545-55.
25. Castaneda C, Layne JE, Munoz-Orians L, Gordon PL, Walsmith J, Foldvari M, et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care 2002;25:2335-41.
26. Zisser HC. Polycystic ovary syndrome and pregnancy: is metformin the magic bullet? Diabetes Spectr 2007;20:85-9.
27. Zeng XL, Zhang YF, Tian Q, Xue Y, An RF. Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: a meta-analysis. Med 2016;95:e4526.
28. Tomova A, Deepinder F, Robeva R, Kirilov G, Mechandjiev Z, Kumanov P. Anti-Müllerian hormone in women with polycystic ovary syndrome before and after therapy with metformin. Horm Metab Res 2011;43:723-7.
Files
IssueVol 63 No 4 (2025) QRcode
SectionOriginal Articles
Keywords
Metformin Ovulation Pregnancy Anti-mullerian hormone
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
AL-Qarawy AKM. The Impact of Metformin Treatment on Serum Level of AMH and on Ovulation and Pregnancy Outcome in Women With PCOS. Acta Med Iran. 2025;63(4):225-230.